Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic

August 2010
TEST DATA_New England Patriots EDSYS;08032010, p20
No abstract available.


Related Articles

  • Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal ± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts. Giugliano, Dario; Tracz, Mariusz; Shah, Sanjiv; Calle-Pascual, Alfonso; Mistodie, Cristina; Duarte, Rui; Sari, Ramazan; Woo, Vincent; Jiletcovici, Alina O.; Deinhard, Jürgen; Wille, Simone A.; Kiljański, Jacek // Diabetes Care;Feb2014, Vol. 37 Issue 2, p372 

    OBJECTIVE We compared two strategies initiating and intensifying insulin treatment and tested for noninferiority of premixed insulin to basal ± mealtime insulin analog in patients eating light breakfasts. RESEARCH DESIGN AND METHODS This randomized, open-label, 48-week study compared two...

  • Insulin Detemir: A Review of its Use in the Management of Diabetes Mellitus. Keating, Gillian M.; Evans, M.; Kabadi, U. M.; Karnieli, E.; Mooradian, A. D.; Rašlová, K.; Ross, S. A. // Drugs;2012, Vol. 72 Issue 17, p2255 

    Insulin detemir (Levemir®) is a long-acting insulin analogue indicated for use as basal insulin therapy in patients with type 1 or 2 diabetes mellitus. The protracted action of insulin detemir is explained by increased self-association and reversible binding to albumin, which slows its...

  • Premixed Insulin Analogues for the Treatment of Diabetes Mellitus. Garber, Alan J. // Drugs;2006, Vol. 66 Issue 1, p31 

    Premixed insulin analogues, consisting of rapid-acting and intermediate-acting insulin analogues, were developed to more closely mimic physiological endogenous insulin secretion and meet the needs of patients who require both basal and prandial insulin but wish to limit the number of daily...

  • Comparison of Twice-Daily Injection of Biphasic Insulin Lispro and Basal-Bolus Therapy in Insulin Naive Patients with Type 2 Diabetes. Yamada, Satoru; Masuda, Haruka; Kitaoka, Akira; Shiono, Kaoru; Atsuda, Koichiro; Irie, Junichiro; Shimada, Akira // Diabetes;Jun2007 Supplement 1, Vol. 56, pA537 

    The article presents a comparative study of injection of Premixed Insulin Lispro (Mix50) and Basal-Bolus therapy (BB) in insulin naive type 2 diabetic patients treated with oral hypoglycaemic agent (OHA). According to the findings, twice-daily injection of Mix50 has similar effect to control...

  • Options for Intensification with Biphasic Insulins in Patients with Type 2 Diabetes Not Achieving Glycemic Control. Warren, M // Internet Journal of Family Practice;2013, Vol. 11 Issue 1, p1 

    Background: In type 2 diabetes, simple, convenient and effective regimens should encourage timely insulin initiation and improve outcomes. Long- and rapid-acting insulin analogues more closely mimic endogenous basal/prandial insulin secretion than human equivalents. Premixed insulin analogues...

  • Insulin Management of Type 2 Diabetes Mellitus. PETZNICK, ALLISON // American Family Physician;7/15/2011, Vol. 84 Issue 2, p183 

    Insulin therapy is recommended for patients with type 2 diabetes mellitus and an initial A1C level greater than 9 percent, or if diabetes is uncontrolled despite optimal oral glycemic therapy. Insulin therapy may be initiated as augmentation, starting at 0.3 unit per kg, or as replacement,...

  • Concomitant Oral Antihyperglycemic Agent Use and Associated Treatment Outcomes After Initiation of Insulin Therapy. William Herman; John Buse; Richard Arakaki; Kathleen Dungan; Honghua Jiang; Jennie Jacobson; Jessie Fahrbach // Endocrine Practice;Jul2011, Vol. 17 Issue 4, p563 

    Objective: To compare outcomes in patients with type 2 diabetes initiating insulin lispro mix 75/25 (75% insulin lispro protamine suspension and 25% lispro) or insulin glargine therapy, stratified by baseline oral antihyperglycemic agent (OHA) use.Methods: We performed a post hoc analysis of...

  • Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents. Rosenstock, Julio; Ahmann, Andrew J.; Colon, Gildred; Scism-Bacon, Jamie; Jiang, Honghua; Martin, Sherry // Diabetes Care;Jan2008, Vol. 31 Issue 1, p20 

    OBJECTIVE -- The purpose of this study was to compare two analog insulin therapies (prandial premixed therapy [PPT] versus basal/bolus therapy [BBT]) in type 2 diabetic patients previously treated with insulin glargine (≥30 units/day) plus oral agents, with the aim of demonstrating...

  • Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents. Bretzel, Reinhard G.; Eckhard, Michael; Landgraf, Wolfgang; Owens, David R.; Linn, Thomas // Diabetes Care;Nov2009 Supplement, Vol. 32, pS260 

    The article discusses a study called A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantus once daily or Lispro at mealtime in type 2 diabetic patients failing Oral treatment (APOLLO) trial. It notes that the study showed that a once daily basal insulin...

  • Lispro Insulin and Metformin Versus Other Combination in the Diabetes Mellitus Type 2 Management after Secondary Oral Antidiabetic Drug Failure. Kokic, Slaven; Bukovic, Damir; Radman, Maja; Capkun, Vesna; Gabric, Nikica; Lesko, Vesna; Karelovic, Deni; Stanceric, Tajana // Collegium Antropologicum;Jun2003, Vol. 27 Issue 1, p181 

    The purpose of the study was to find out differences between treatments of diabetes type 2 after secondary oral antidiabetic drug failure. Three different methods of treatment were compared: lispro insulin in combination with metformin, glimepiride and metformin combination or two daily doses of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics